Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's Disease
Hilary Grosso Jasutkar, Stephanie Oh, M. Maral Mouradian
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 207-237
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches
Marija Vidović, Milena Rikalović
Cells (2022) Vol. 11, Iss. 11, pp. 1732-1732
Open Access | Times Cited: 93
Advances in understanding the function of alpha-synuclein: implications for Parkinson’s disease
Paolo Calabresi, Giulia Di Lazzaro, Gioia Marino, et al.
Brain (2023) Vol. 146, Iss. 9, pp. 3587-3597
Open Access | Times Cited: 60
Alpha Synuclein: Neurodegeneration and Inflammation
Gianluigi Forloni
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5914-5914
Open Access | Times Cited: 57
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions
Grace m. Kuo, Ramhari Kumbhar, W. Frank Blair, et al.
Molecular Neurodegeneration (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 3
A Pivotal Role of Nrf2 in Neurodegenerative Disorders: A New Way for Therapeutic Strategies
Síbel Süzen, Paolo Tucci, Elisabetta Profumo, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 692-692
Open Access | Times Cited: 46
(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression
Xingming Wang, Jianjun Yang, Kenji Hashimoto
Neuroscience & Biobehavioral Reviews (2022) Vol. 139, pp. 104762-104762
Open Access | Times Cited: 41
The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases
Elena Possemato, Livia La Barbera, Annalisa Nobili, et al.
Ageing Research Reviews (2023) Vol. 87, pp. 101907-101907
Closed Access | Times Cited: 40
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice
Franziska Richter, Miloš Stanojlović, Christopher Käufer, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 1, pp. 97-116
Open Access | Times Cited: 23
Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422
Louise Buur, Jonas Wiedemann, Frank Larsen, et al.
Movement Disorders (2024) Vol. 39, Iss. 6, pp. 936-944
Open Access | Times Cited: 13
Tackling vascular risk factors as a possible disease modifying intervention in Parkinson’s disease
Anne E. Visser, Nienke M. de Vries, Edo Richard, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Targeting PAAN/MIF nuclease activity in parthanatos-associated brain diseases
Lauren Guttman, Yang Liu, Meilian Liu, et al.
Advances in pharmacology (2025), pp. 1-26
Closed Access | Times Cited: 1
Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer’s and Parkinson’s Diseases
Nidhi Puranik, Minseok Song
Neurology International (2025) Vol. 17, Iss. 2, pp. 26-26
Open Access | Times Cited: 1
Targeting Nrf2 signaling pathway by quercetin in the prevention and treatment of neurological disorders: An overview and update on new developments
Mohammad Yasin Zamanian, Afsaneh Soltani, Zahra Khodarahmi, et al.
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 6, pp. 1050-1064
Closed Access | Times Cited: 22
Gut–Brain Axis in Focus: Polyphenols, Microbiota, and Their Influence on α-Synuclein in Parkinson’s Disease
Elizabeth Riegelman, Kathy S. Xue, Jia-Sheng Wang, et al.
Nutrients (2024) Vol. 16, Iss. 13, pp. 2041-2041
Open Access | Times Cited: 7
Drug delivery pathways to the central nervous system via the brain glymphatic system circumventing the blood‐brain barrier
Xiang Wang, Yue Yin, Huaijuan Zhou, et al.
Exploration (2024)
Open Access | Times Cited: 7
Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric Disorders
Jiajing Shan, Kenji Hashimoto
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4951-4951
Open Access | Times Cited: 26
Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease
Scott G. Allen, Richard M. Meade, Lucy L. White Stenner, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 14
Posttranslational Modifications ofα-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases
Kambiz Hassanzadeh, Jun Liu, Santhosh Chandar Maddila, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 6, pp. 1254-1290
Closed Access | Times Cited: 5
Small molecule modulators of Alpha-Synuclein Aggregation and Toxicity: Pioneering an Emerging Arsenal Against Parkinson’s Disease
Ishfaq Ahmad Ahanger, Tanveer Ali Dar
Ageing Research Reviews (2024) Vol. 101, pp. 102538-102538
Closed Access | Times Cited: 5
Chalcones as Potential Ligands for the Treatment of Parkinson’s Disease
Ewelina Królicka, Katarzyna Kieć‐Kononowicz, Dorota Łażewska
Pharmaceuticals (2022) Vol. 15, Iss. 7, pp. 847-847
Open Access | Times Cited: 21
Bioorthogonal Aptamer‐ATTEC Conjugates for Degradation of Alpha‐Synuclein via Autophagy‐Lysosomal Pathway
Xiaofeng Liao, Geng Qin, Zhenqi Liu, et al.
Small (2023) Vol. 20, Iss. 8
Open Access | Times Cited: 12
Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease
Haoran Peng, Siyuan Chen, Shaopu Wu, et al.
Journal of the Neurological Sciences (2023) Vol. 451, pp. 120730-120730
Open Access | Times Cited: 11
Molecular mechanism of α-synuclein aggregation on lipid membranes revealed
Alexander J. Dear, Xiangyu Teng, Sarah R. Ball, et al.
Chemical Science (2024) Vol. 15, Iss. 19, pp. 7229-7242
Open Access | Times Cited: 4
α-Synuclein pathology as a target in neurodegenerative diseases
Hye-Jin Park, Tae‐In Kam, Valina L. Dawson, et al.
Nature Reviews Neurology (2024)
Closed Access | Times Cited: 4
Multi‐Targeting Macrocyclic Peptides as Nanomolar Inhibitors of Self‐ and Cross‐Seeded Amyloid Self‐Assembly of α‐Synuclein
Simon Hornung, Dominik P. Vogl, Denise Naltsas, et al.
Angewandte Chemie (2025)
Closed Access
Page 1 - Next Page

Scroll to top